“Biogen Idec (BIIB) has been reiterated by TheStreet Ratings as a buy with a ratings score of A- . The company’s strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.”
,” TheStreet’s analyst wrote.
Other equities research analysts have also recently issued reports about the stock. Analysts at Argus reiterated a buy rating on shares of Biogen Idec in a research note to investors on Monday. They now have a $160.00 price target on the stock. Separately, analysts at Credit Suisse raised their EPS on shares of Biogen Idec in a research note to investors on Friday, February 8th. They now have an outperform rating and a $185.00 price target on the stock. They previously had a $175.00 price target on the stock. Finally, analysts at Citigroup upgraded shares of Biogen Idec from a neutral rating to a buy rating in a research note to investors on Thursday, February 7th. They now have a $187.00 price target on the stock, up previously from $160.00.
Fourteen research analysts have rated the stock with a buy rating, one has assigned an overweight rating, and fifteen have given a hold rating to the stock. Biogen Idec has a consensus rating of overweight and a consensus target price of $172.12.
Biogen Idec opened at 165.35 on Wednesday. Biogen Idec has a 52-week low of $114.53 and a 52-week high of $167.35. The stock’s 50-day moving average is currently $151.. The company has a market cap of $39.074 billion and a price-to-earnings ratio of 28.57.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.